Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience
MetadataShow full item record
Background: Cytomegalovirus (CMV) establishes a lifelong infection that is efficiently controlled by the immune system; this infection can be reactivated in case of immunosuppression such as following solid organ transplantation. CMV viraemia has been associated with CMV disease, as well as increased mortality and allograft failure. Prophylactic antiviral medication is routinely given to renal transplant recipients, but reactivation during and following cessation of antiviral prophylaxis is known to occur. The aims of this study were to assess the incidence, timing and impact of CMV viraemia in renal transplant recipients and to determine the level of viraemia associated with adverse clinical outcomes. Methods: Data from all adult (18 years and over) Western Australian renal transplant recipients transplanted between 1 January 2007 and 31 December 2012 were obtained from the Australia and New Zealand Dialysis and Transplant registry and were supplemented with data obtained from clinical records. Potential risk factors for detectable CMV viraemia (=600 copies/ml) and all-cause mortality were assessed using univariable analysis and Cox Proportional Hazards Regression. Results: There were 438 transplants performed on 435 recipients. The following factors increased the risk of CMV viraemia with viral loads =600 copies/ml: Donor positive/Recipient negative status; receiving a graft from a deceased donor; and receiving a graft from a donor aged 60 years and over. CMV viraemia with viral loads =656 copies/ml was a risk factor for death following renal transplantation, as was being aged 65 years and above at transplant, being Aboriginal and having vascular disease. Importantly 37% of the episodes of CMV viraemia with viral loads =656 copies/ml occurred while the patients were expected to be on CMV prophylaxis. Conclusions: CMV viraemia (=656 copies/ml) was associated with all-cause mortality in multivariable analysis, and CMV viraemia at =656 copies/ml commonly occurred during the period when renal transplant recipients were expected to be on antiviral prophylaxis. A greater vigilance in monitoring CMV levels if antiviral prophylaxis is stopped prematurely or poor patient compliance is suspected could protect some renal transplant recipients from adverse outcomes such as premature mortality.
Showing items related by title, author, creator and subject.
Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western AustraliaThompson, G.; Boan, P.; Baumwol, J.; Chakera, Aron; MacQuillan, G.; Swaminathan, S.; Lavender, M.; Flexman, J.; James, I.; John, M. (2018)Prevention of cytomegalovirus (CMV) infection remains an important aspect of improving long term outcomes of solid organ transplantation and currently relies on prophylactic antiviral medication and early detection of ...
Antigen-specific T cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide immunosuppression following renal transplantationChakera, Aron; Bennett, S.; Lawrence, S.; Morteau, O.; Mason, P.; O'Callaghan, C.; Cornall, R. (2011)Infection with the polyoma virus BK (BKV) is a major cause of morbidity following renal transplantation. Limited understanding of the anti-viral immune response has prevented the design of a strategy that balances treatment ...
Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?Wong, G.; Chakera, Aron; Chapman, J.; Chadban, S.; Pilmore, H.; Craig, J.; Lim, W. (2017)© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons LtdBackground: The role of cytomegalovirus (CMV) in cancer development after transplantation remains uncertain. We aimed to determine the association between ...